silke gillessen
@Silke_Gillessen
Followers
3K
Following
2K
Media
68
Statuses
1K
Medical Oncologist, Oncology Institute of Southern Switzerland, views are mine
Switzerland
Joined November 2013
Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer: Meta-Analysis https://t.co/K1KnuMLrZg Meta-analysis of over 10,000 patients from 13 randomized trials found that the survival benefit of androgen deprivation therapy
1
38
101
We are looking for a talented genitourinary medical oncologist to join our group. Join a great team focused on eradicating GU cancers! https://t.co/zp0iyJ6rS7
0
8
44
Another important topic for @APCCC_Lugano! Come and join us, registration is open via https://t.co/fPN1UjMfsX and deadline for abstract submission is close!
⭐️Neeraj and I discuss how the EMBARK study #ESMO25 gives us a path forward for intermittent treatment for certain patients with metastatic hormone sensitive prostate cancer. LOVE this discussion. Full video click here 👉 https://t.co/bohtDqdULW After listening to his great
1
3
11
The mHSPC space becomes more and more interesting! Come and participate in the discussions @APCCC_Lugano register via https://t.co/fPN1UjMfsX!
Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 Phase III study out on Annals of Oncology https://t.co/uUnQ6N6A13 CAPItello-281 In PTEN-deficient metastatic hormone-sensitive #ProstateCancer , adding the AKT inhibitor
1
10
37
Excellent and talented fellows like you are always welcome at the IOSI!
@ZilliThomas @myESMO @royalmarsdenNHS @AnnelaureCattin @TheCrick Thank you so much, Thomas! Grateful for my previous time at the IOSI with the mentorship of @Silke_Gillessen and @UrsulaVogl!
0
0
5
A warm invite to all, we wait for you at #APCCC26 ⭐ Full details & submission https://t.co/U46NMslfll
@Silke_Gillessen & @AOmlin
@OncoAlert 🚨 @fabioturco92 @Prof_IanD @drjefstathiou @Prof_Nick_James @ChrisSweens1 @BertrandTOMBAL @ZilliThomas @neerajaiims @bjartell
apccc.org
Dear Colleagues at #ESMO25 An honor to present our faculty🚨 @Silke_Gillessen and @AOmlin straight from Berlin who discuss about: The Radioligand Therapy Session on #ProstateCancer VERY hot Topics and some that will spark up conversation in Lugano🇨🇭 for #APCCC26
@APCCC_Lugano
0
12
24
Thanks Rana!
EORTC Announces Final Positive Overall Survival Results From The PEACE-3 Trial. Congrats @Silke_Gillessen @BertrandTOMBAL @myESMO @OncoAlert #ESMO25
0
5
12
Ultrahypofractionated radiotherapy in one or two sessions for localized prostate cancer: a review of the evidence and future perspectives https://t.co/o8WKuojSsg Review compares single- and two-session approaches in SBRT and HDR brachytherapy for localized #ProstateCancer .
1
9
16
Don‘t forget to submit your abstracts! And we will see you in Lugano end of April 2026
🚨 Big News from #APCCC26 🚨 APCCC is opening a Call for Abstracts, creating new opportunities for younger investigators & the next generation of leaders in advanced prostate cancer! Full details & submission 👉 https://t.co/U46NMslfll 📅 Key Dates: 🔹 Submission opens: 1 Sept
1
9
20
Call for abstracts is open. APCCC 2026 (Lugano, 30 Apr–2 May) is a space where evidence meets consensus in advanced prostate cancer. #APCCC26 @APCCC_Lugano @OncoAlert @PCFnews @Uromigos #prostatecancer
0
12
30
Please share with all interested colleagues!
🚨 Big News from #APCCC26 🚨 APCCC is opening a Call for Abstracts, creating new opportunities for younger investigators & the next generation of leaders in advanced prostate cancer! Full details & submission 👉 https://t.co/LdNISUG3OK 📅 Key Dates: 🔹 Submission opens: 1 Sept
0
19
40
Important data. We are testing de-escalation in deep responders in the DE-ESCALATE trial. Anyone interested to join please contact @BertrandTOMBAL or me. We will discuss the topic @APCCC_Lugano, register and participate in the discussions
CHAARTED Ten-year survival rates: Time to re-think de-escalation! Achieving a PSA nadir below 0.2 ng/mL within 6 months is a strong predictor of overall survival, supporting its role in response-adapted de-escalation strategies. @Annals_Oncology @myESMO @eaonc @ERPlimackMD
1
20
50
Biomarkers in Localized Prostate Cancer: From Diagnosis to Treatment https://t.co/h1fFOTFr8w This review explores advances beyond prostate-specific antigen (PSA) in the detection and management of localized #ProstateCancer , focusing on emerging urinary biomarkers (PCA3,
0
22
39
warm invite to the Advanced Prostate Cancer Consensus Conference #APCCC26 in Lugano🇨🇭 👉REGISTER HERE: https://t.co/zPDe03TBd7 In an era of rapid innovation and expanding treatment options for advanced #ProstateCancer , APCCC provides a vital forum for clinicians and
4
20
31
Prostate Imaging for Recurrence Reporting: User Guide https://t.co/arDE71zcSh The Prostate Imaging for Recurrence Reporting (PI-RR) system, introduced in 2021, provides a standardized framework for interpreting pelvic MRI in patients with suspected #ProstateCancer recurrence
0
16
33
Management of patients with Advanced #ProstateCancer : A Report from #APCCC24 LINK TO ARTICLE👇 https://t.co/fmUzljweS4 The Advanced Prostate Cancer Consensus Conference (APCCC) highlights significant advances in prostate cancer management while underscoring areas where
3
43
77
Congrats, Rana!
We’re proud to present the KidneyCAN Catalyst Award to Dr. Rana McKay of UC San Diego. Dr. McKay is a leader whose work has helped move the field of kidney cancer forward through groundbreaking research, clinical collaboration, and a deep commitment to patients and advocacy. Her
0
0
1
We’re proud to present the KidneyCAN Catalyst Award to Dr. Rana McKay of UC San Diego. Dr. McKay is a leader whose work has helped move the field of kidney cancer forward through groundbreaking research, clinical collaboration, and a deep commitment to patients and advocacy. Her
2
10
55
#KCRS25 Oral Abstract: @DrChoueiri @DanaFarber shares results from the ARC-20 study: casdatifan + cabozantinib shows promise in previously treated clear cell RCC. Read all the abstracts: https://t.co/Vjemnyfdh7 Register: https://t.co/wOSjrfnhZ2
#AcceleratingCures
0
5
23
Join us #KCRS2025 —unmissable how to design and excite from other trials and bring them into kidney cancer —@kidneycan @VivekSubbiah @montypal
0
11
37